Leerink Partners Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $600
DBS Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Buy Rating Affirmed for Vertex Pharmaceuticals on Promising Pain Management Drug Prospects
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven by 'Strong AI Demand' And 'Margin Expansion'
Vortex Energy Brief: Says Completed Phase 1 Exploration at the Fire Eye Uranium Property, Saskatchewan and Amends Option Terms